Phenprocoumon and Apixaban: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Phenprocoumon
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both apixaban (Eliquis) and phenprocoumon are blood thinners, just from different families. Apixaban blocks a clotting protein called factor Xa, and phenprocoumon works through vitamin K. Taking them together thins your blood more than either one alone, which raises your risk of serious bleeding.
Watch for warning signs like unusual bruising, pink or red urine, black or bloody stools, nosebleeds that won't stop, or bleeding gums. If you notice heavy or sudden bleeding, get emergency help right away. The good news is your care team knows how to handle this, and they will guide any changes. Never start or stop either drug on your own.
Additive anticoagulation. Apixaban (direct factor Xa inhibitor) plus phenprocoumon (vitamin K antagonist) produces overlapping anticoagulant effects and a clinically significant increase in bleeding risk. Neither is a prodrug; this is a pharmacodynamic, not metabolic, interaction. Pharmacodynamic studies with apixaban plus enoxaparin showed a 50 to 60 percent rise in anti-Xa activity, illustrating additivity.
- Direction: increased anticoagulant effect and bleeding risk.
- Evidence: probable; severity major.
- Management: avoid concurrent use except during appropriate transition; discontinue apixaban if active pathological bleeding occurs. Apixaban's PD effect persists >=24 h. A specific reversal agent is available; PCC, aPCC, or rFVIIa may be considered. During PCC use, PT/INR/aPTT and anti-FXa are not reliable.
What happens
An increased risk of bleeding and can cause serious, potentially fatal bleeding
Interaction Deep Dive
Giving apixaban, an inhibitor of factor Xa, together with another anticoagulant heightens the likelihood of bleeding. Pharmacodynamic interaction studies involving apixaban demonstrated a 50% to 60% rise in anti-factor Xa activity when apixaban and enoxaparin were given together. Should active pathological bleeding develop, apixaban should be stopped. There is an agent that reverses apixaban's anti-factor Xa activity. Apixaban's pharmacodynamic effect can be anticipated to last for at least 24 hours following the final dose. Patients should be counseled about the signs and symptoms of blood loss and instructed to report these right away or proceed to an emergency room. Options that may be considered include prothrombin complex concentrate (PCC), activated prothrombin complex concentrate, or recombinant factor VIIa. If PCCs are administered, it is neither useful nor recommended to monitor apixaban's anticoagulant effect via a clotting test (PT, INR, or aPTT) or anti-factor Xa (FXa) activity. Activated oral charcoal decreases apixaban absorption, which in turn diminishes apixaban exposure1.
Why it happens (mechanism)
Additive anticoagulation
How to manage this interaction
Two blood thinners at once meaningfully raises bleeding risk, so this combination is usually only used briefly and deliberately, such as when switching from one anticoagulant to the other. Your care team decides that timing.
- Keep taking both exactly as prescribed unless your prescriber tells you otherwise. Do not start, stop, or overlap them on your own.
- Learn the bleeding warning signs: unusual bruising, blood in urine or stool, black stools, prolonged nosebleeds, coughing or vomiting blood.
- Report bleeding immediately or go to an emergency room. Reversal agents exist and hospitals can treat serious bleeding.
Ask your pharmacist to review your full medication list for other bleeding risks.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In investigations of pharmacodynamic drug interactions involving apixaban, an increase of 50% to 60% in anti-factor Xa activity was seen when apixaban and enoxaparin were given together 1.
Common questions
Can I take Phenprocoumon and Apixaban together?
Apixaban and phenprocoumon together add up to a much higher bleeding risk, so this overlap should be managed closely by your care team. Know the signs of bleeding and seek emergency care immediately if they appear. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Phenprocoumon and Apixaban interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Phenprocoumon and Apixaban interaction managed?
Two blood thinners at once meaningfully raises bleeding risk, so this combination is usually only used briefly and deliberately, such as when switching from one anticoagulant to the other. Your care team decides that timing. Keep taking both exactly as prescribed unless your prescriber tells you otherwise. Do not start, stop, or overlap them on your own. Learn the bleeding warning signs: unusual b… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Phenprocoumon or Apixaban need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ELIQUIS(R) oral film coated tablets, apixaban oral film coated tablets. Bristol-Myers Squibb Company (per Dailymed), Princeton, NJ, 2024. DailyMed
Keep reading about Apixaban
Keep reading about Phenprocoumon
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist